EP4347636A4 - BCMA targeting trispecific proteins and methods of use - Google Patents

BCMA targeting trispecific proteins and methods of use

Info

Publication number
EP4347636A4
EP4347636A4 EP22816832.4A EP22816832A EP4347636A4 EP 4347636 A4 EP4347636 A4 EP 4347636A4 EP 22816832 A EP22816832 A EP 22816832A EP 4347636 A4 EP4347636 A4 EP 4347636A4
Authority
EP
European Patent Office
Prior art keywords
methods
specific proteins
bcma targeting
tri
targeting tri
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP22816832.4A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4347636A2 (en
Inventor
Holger Wesche
Liping Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harpoon Therapeutics Inc
Original Assignee
Harpoon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harpoon Therapeutics Inc filed Critical Harpoon Therapeutics Inc
Publication of EP4347636A2 publication Critical patent/EP4347636A2/en
Publication of EP4347636A4 publication Critical patent/EP4347636A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP22816832.4A 2021-06-03 2022-06-02 BCMA targeting trispecific proteins and methods of use Withdrawn EP4347636A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163196595P 2021-06-03 2021-06-03
US202163288124P 2021-12-10 2021-12-10
PCT/US2022/031917 WO2022256499A2 (en) 2021-06-03 2022-06-02 Bcma targeting trispecific proteins and methods of use

Publications (2)

Publication Number Publication Date
EP4347636A2 EP4347636A2 (en) 2024-04-10
EP4347636A4 true EP4347636A4 (en) 2025-04-16

Family

ID=84323567

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22816832.4A Withdrawn EP4347636A4 (en) 2021-06-03 2022-06-02 BCMA targeting trispecific proteins and methods of use

Country Status (6)

Country Link
US (1) US20240254250A1 (https=)
EP (1) EP4347636A4 (https=)
JP (1) JP2024520727A (https=)
AU (1) AU2022286960A1 (https=)
CA (1) CA3220878A1 (https=)
WO (1) WO2022256499A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9708412B2 (en) 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
EP3493844A4 (en) 2016-05-20 2021-03-24 Harpoon Therapeutics Inc. SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
MX2020003915A (es) 2017-10-13 2020-10-08 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso.
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020003915A (es) * 2017-10-13 2020-10-08 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso.
IL315737A (en) * 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
CA3089230A1 (en) * 2018-03-02 2019-09-06 Cdr-Life Ag Trispecific antigen binding proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MADAN SUMIT ET AL: "An Interim Report on a Phase 1/2 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC ) Targeting B Cell Maturation Antigen for the Treatment of Relapsed/Refractory Multiple Myeloma", BLOOD, vol. 138, no. Supplement 1, 5 November 2021 (2021-11-05), AMSTERDAM, NL, pages 1654 - 1654, XP093254414, ISSN: 0006-4971, Retrieved from the Internet <URL:https://pdf.sciencedirectassets.com/778769/1-s2.0-S0006497121X00420/1-s2.0-S0006497121036211/main.pdf?hash=3e779193d3185a4ceed201c78804dd441a2c69f29eb7fbe2c8fdb2a519a23e7e&host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&pii=S0006497121036211&tid=spdf-574e6d81-9389-476a-849e-00f> DOI: 10.1182/blood-2021-148176 *
SCHADE HENNING ET AL: "HPN217-3001: A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217, a Bcma-Targeting T-Cell Engager, in Patients with Relapsed/Refractory Multiple Myeloma", BLOOD, vol. 136, no. Supplement 1, 5 November 2020 (2020-11-05), AMSTERDAM, NL, pages 10 - 10, XP093254418, ISSN: 0006-4971, Retrieved from the Internet <URL:https://pdf.sciencedirectassets.com/778769/1-s2.0-S0006497118X60091/1-s2.0-S0006497118706265/main.pdf?hash=feb54279d9dbdd32743e5d7759a2aca892289191abbb1e61b548e2edd0766559&host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&pii=S0006497118706265&tid=spdf-b4abd735-a816-4b1b-9fd1-d99> DOI: 10.1182/blood-2020-136012 *

Also Published As

Publication number Publication date
WO2022256499A2 (en) 2022-12-08
AU2022286960A1 (en) 2024-01-18
CA3220878A1 (en) 2022-12-08
EP4347636A2 (en) 2024-04-10
US20240254250A1 (en) 2024-08-01
WO2022256499A3 (en) 2023-01-19
JP2024520727A (ja) 2024-05-24

Similar Documents

Publication Publication Date Title
EP4347636A4 (en) BCMA targeting trispecific proteins and methods of use
EP4347637A4 (en) DLL3 as a target for trispecific proteins and methods of use
EP4346788A4 (en) Enantiomeric entactogen compositions and methods of their use
EP3969479A4 (en) EPCAM BINDING PROTEINS AND METHODS OF USE
EP3917564A4 (en) ANTI-CLAUDIN-18 ANTIBODIES AND METHODS OF USE THEREOF
EP3852805A4 (en) ANTI-LILRB2 ANTIBODIES AND METHODS OF USE THEREOF
EP3959318A4 (en) Oligonucleotide compositions and methods of use thereof
EP3694529A4 (en) TRISPECIFIC PROTEINS AND METHOD OF USE
EP1763490A4 (en) ELECTRODEIONIZATION DEVICE AND USE METHOD
CA3262480A1 (en) Fibroblast activation protein-targeted compositions and methods of use thereof
EP4211240A4 (en) CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF
EP4004051A4 (en) IMMUNOMODULATORY ANTIBODIES AND METHODS OF USE THEREOF
EP4308095A4 (en) GLYCOGEN SYNTHASE 1 (GYS1) INHIBITORS AND METHODS OF USE THEREOF
EP3946354A4 (en) HETEROMULTIMER PROTEINS AND METHODS OF USE THEREOF
EP4229063A4 (en) NOVEL PIKFYVE INHIBITORS AND METHODS OF USE THEREOF
MA53492A (fr) Anticorps anti-cd33 et leurs méthodes d&#39;utilisation
MA52014A (fr) Anticorps anti-klk5 et méthodes d&#39;utilisation
EP3735242A4 (en) METALLO-BETA-LACTAMASE INHIBITORS AND METHOD OF USING THEREOF
EP3743109A4 (en) MICA / B ANTIBODIES AND METHOD OF USE
MA53427A (fr) Inhibiteurs de l&#39;arginase et leurs méthodes d&#39;utilisation
EP3773623A4 (en) TRANS ANTIGEN TARGETING IN HETEROGENIC CARCINOMA AND METHOD OF USING IT
EP4308110A4 (en) Compounds targeting fibroblast-activation protein and methods of use thereof
EP3906038A4 (en) ADENOVIRUS AND METHODS OF USE OF ADENOVIRUS
EP4294800A4 (en) APOL1 INHIBITORS AND METHODS OF USE
EP4003391A4 (en) PEPTIDES AND METHODS OF USE THEREOF

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20231219

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07K0014705000

Ipc: C07K0016280000

A4 Supplementary search report drawn up and despatched

Effective date: 20250319

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20250313BHEP

Ipc: C07K 14/725 20060101ALI20250313BHEP

Ipc: C07K 14/705 20060101ALI20250313BHEP

Ipc: C07K 16/28 20060101AFI20250313BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20251009